Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients
| Autor: | Hiroki Murayama, Mitsutoshi Toda, Isao Tsumiyama, Naotsugu Oyama, Tomoko Taniguchi, Yohei Shinfuku, Yoshio Tanaka |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Exacerbation Adolescent endocrine system diseases Disease 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine Product Surveillance Postmarketing Medicine Humans Pharmacology (medical) Vildagliptin Diabetic Nephropathies Glycemic Macrovascular disease Aged Pharmacology Glycated Hemoglobin Dipeptidyl-Peptidase IV Inhibitors business.industry Incidence (epidemiology) Type 2 Diabetes Mellitus nutritional and metabolic diseases General Medicine Odds ratio Middle Aged medicine.disease Diabetes Mellitus Type 2 030220 oncology & carcinogenesis Female business 030217 neurology & neurosurgery medicine.drug |
| DOI: | 10.6084/m9.figshare.7800971.v1 |
| Popis: | Background: Vildagliptin is indicated for type 2 diabetes mellitus (T2DM); however, the onset and exacerbation of diabetic complications in Japanese T2DM patients treated with vildagliptin is unknown. Research design and methods: This 2-year post-marketing surveillance (PMS) assessed the real-world safety and efficacy of vildagliptin therapy in 19,218 Japanese T2DM patients. The relationship between the incidence of macro- and microvascular complications with patient characteristics and changes in glycemic control (HbA1c) were evaluated. Results: The incidences of macro- and microvascular diseases were 1.14% and 3.09%, respectively. Patients with HbA1c ≥8.4% had a higher odds ratio (OR) for micro- and macrovascular disease (OR: 2.02 and 1.90) compared with patients with HbA1c Conclusions: Vildagliptin elicited no increases/exacerbations of diabetic complications; this PMS suggested that the incidence of diabetic complications tends to be low in subjects with good HbA1c control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|